FDA Grants Full Approval to mRNA-1273 COVID-19 Vaccine in Children At Increased Risk
mRNA-1273, marketed as Spikevax by Moderna, is now fully approved for individuals aged 6 months through 64 years with high-risk…
ATOPP 2025: Pharmacy Innovation at the Intersection of EOM and Patient Access
Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, discusses how oncology pharmacists can lead value-based care efforts under the Enhanced…
Breaking Through Misconceptions: How Pharmacists Can Shift the Conversation for Vaccines
An expert discusses how pharmacists can overcome common vaccination barriers by addressing misconceptions about vaccine necessity, making strong provider recommendations,…
1042: Early Norepinephrine Use in Septic Shock is Associated with Reduced Mortality
Show notes at pharmacyjoe.com/episode1042. In this episode, I’ll discuss early vs delayed norepinephrine use in patients with septic shock. The…
ATOPP 2025: Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, Highlights Must-See Sessions
Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, discusses the value of the 2025 ATOPP Summit in advancing oncology pharmacy…
Obesity-Linked Exosomes May Drive Tumor Aggressiveness in Triple-Negative Breast Cancer
Obesity and high-fat diets enhance the aggressiveness of triple-negative breast cancer through exosome-mediated mechanisms, revealing new therapeutic targets.
Zanubrutinib Linked to Lower Infection Risk Than Venetoclax Plus Obinutuzumab in Real-World CLL/SLL Study
New research highlights the lower infection risk with zanubrutinib compared to venetoclax in CLL/SLL treatment, offering safer options for patients.
Research Suggests Vitamin D Deficiency Is a Risk Factor for Autism
Discover how vitamin D supplementation may reduce Autism Spectrum Disorder symptoms and improve overall functioning in children with ASD.
Reassessing the Safety and Efficacy of Very Low LDL Cholesterol
Though cholesterol-lowering guidance often touts the achievement of very low levels of low-density lipoprotein (LDL) cholesterol, emerging research demonstrates possible…
Highlights From NLA 2025: Early LDL-C Reduction and Emerging Therapies
The 2025 National Lipid Association (NLA) Scientific Sessions highlighted a strategic shift toward early, aggressive cardiometabolic intervention, underscoring the vital…